Treatment of Primary Biliary Cholangitis in Pregnancy
Pregnancy in a patient with primary biliary cholangitis (PBC) requires specialist input to guide therapy safely across conception, pregnancy, and the post-partum period. Expert consultation is recommended for all pregnant patients with PBC.
In non-cirrhotic patients, pregnancy is generally well tolerated, but active specialist oversight remains essential. The therapeutic approach must account for both the underlying condition and the safety profile of any agent at each stage of pregnancy.
Treatment approach (partial summary)
Management centres on continuing an established oral bile acid therapy from conception through the post-partum period. Where pruritus is present, certain agents are considered appropriate at specific stages of pregnancy — the full protocol specifies which options apply, at which stages, and what additional clinical considerations shape the decision.
References
DOI: 10.1002/hep.32117
- EASL recommends expert consultation for all pregnant patients to guide therapy, noting that pregnancy is typically well tolerated in non-cirrhotic patients with PBC.
- EASL recommends the continued use of UDCA in pregnancy, even though supporting data are limited.
- Pruritus management is important and may require specialist advice, noting that rifampicin has been used by experts during the third trimester (III, 1).
- Additionally, cholestyramine and rifampicin (third trimester onwards) are considered safe in pregnancy, although the data are limited.
View source ↗